Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Reneo Pharmaceuticals, Inc. RPHM NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
47/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Reneo Pharmaceuticals, Inc. (RPHM) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 4 Buy, 3 Hold.

RPHM Analyst Ratings

Buy
7
Ratings
4 Buy
3 Hold
Based on 7 analysts giving stock ratings to Reneo Pharmaceuticals, Inc. in the past 3 months
Rating breakdown
Buy
4 57%
Hold
3 43%
57%
Buy
4 analysts
43%
Hold
3 analysts
0%
Sell
0 analysts

People Also View

RPRX
RPRX
Royalty Pharma plc
$48.82
+0.81%
 SMMT
SMMT
Summit Therapeutics Inc.
$20.85
+4.09%
 CELC
CELC
Celcuity Inc.
$120.85
+0.37%
 APLS
APLS
Apellis Pharmaceuticals, Inc.
$40.85
+0.02%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 LEGN
LEGN
Legend Biotech Corporation
$18.69
+5.65%
 ADPT
ADPT
Adaptive Biotechnologies Corporation
$14.53
+2.83%
 VIR
VIR
Vir Biotechnology, Inc.
$10.05
+7.95%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message